Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
Nicolas Gendron, Research Fellow and Hematologist at Boston Children’s Hospital, shared a post on LinkedIn about a recent article he and Nûn Kalim Bentounes co-authored, published in Journal of Thrombosis and Haemostasis, adding:
“Very happy to have been invited to write this comment with Nûn Bentounes for Journal of Thrombosis and Haemostasis (JTH), following the very nice study by Mohamed Ghalloussi, Georges Jourdi and Demagny Julien, showing the possibility of using pre-loaded activated carbon tubes (DOAC-Stop) published in the same journal.
The DOAC become undetectable in more than 96% of cases. Routine and specialized hemostasis tests (AT, PC, PS, lupus anticoagulant, etc.) find reliable and interpretable values. A simple, elegant and upstream solution
DOAC interference and resulting diagnostic errors result in uninterpretable results, repeated examinations, wasted resources, and unnecessary patient travel, all of which are incompatible with the emerging concept of sustainable anticoagulation and its true environmental cost.
Beyond innovation, this editorial gives us the opportunity to ask a more fundamental question:
Do we really need all these hemostasis tests in patients on DOACs?
The answer: often, no. In particular for thrombophilia check-ups, which are still too often prescribed and do not comply with the recommendations.
Our message: to combine this innovation with computerized prescribing systems, which guide clinicians to the right examination, for the right patient, at the right time with the right tube, and a robust antithrombotic stewardship program.”
Title: Charcoal for direct oral anticoagulant removal: toward appropriate prescribing and sustainable anticoagulation?
Authors: Nûn Kalim Bentounes, Nicolas Gendron
Other posts featuring Nicolas Gendron on Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause